

# Barbora Brodská

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4168935/publications.pdf>

Version: 2024-02-01

26  
papers

406  
citations

840776  
11  
h-index

794594  
19  
g-index

31  
all docs

31  
docs citations

31  
times ranked

682  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | <i>NPM1</i> and <i>DNMT3A</i> mutations are associated with distinct blast immunophenotype in acute myeloid leukemia. <i>Oncolmunology</i> , 2022, 11, 2073050.   | 4.6 | 1         |
| 2  | Chemotherapy-Induced Survivin Regulation in Acute Myeloid Leukemia Cells. <i>Applied Sciences</i> (Switzerland), 2021, 11, 460.   | 2.5 | 3         |
| 3  | Group I p21-activated kinases in leukemia cell adhesion to fibronectin. <i>Cell Adhesion and Migration</i> , 2021, 15, 18-36.   | 2.7 | 7         |
| 4  | NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization. <i>Scientific Reports</i> , 2021, 11, 1084.  | 3.3 | 7         |
| 5  | AML-Related NPM Mutations Drive p53 Delocalization into the Cytoplasm with Possible Impact on p53-Dependent Stress Response. <i>Cancers</i> , 2021, 13, 3266.   | 3.7 | 6         |
| 6  | Exosomes released by imatinib-resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib-sensitive cells in the presence of imatinib. <i>International Journal of Oncology</i> , 2020, 58, 238-250. | 3.3 | 14        |
| 7  | High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2823.  | 4.1 | 39        |
| 8  | Nucleophosmin in leukemia: Consequences of anchor loss. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 111, 52-62.   | 2.8 | 11        |
| 9  | PAK1, PAK1 <sup>15</sup> , and PAK2: similarities, differences and mutual interactions. <i>Scientific Reports</i> , 2019, 9, 17171.   | 3.3 | 15        |
| 10 | Lifetime-based photoconversion of EGFP as a tool for FLIM. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 266-277.   | 2.4 | 9         |
| 11 | Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin. <i>PLoS ONE</i> , 2018, 13, e0204290.  | 2.5 | 15        |
| 12 | AML-associated mutation of nucleophosmin compromises its interaction with nucleolin. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 103, 65-73.  | 2.8 | 12        |
| 13 | Monitoring of nucleophosmin oligomerization in live cells. <i>Methods and Applications in Fluorescence</i> , 2018, 6, 035016.   | 2.3 | 13        |
| 14 | Localization of AML-related nucleophosmin mutant depends on its subtype and is highly affected by its interaction with wild-type NPM. <i>PLoS ONE</i> , 2017, 12, e0175175.   | 2.5 | 22        |
| 15 | Correlation of PD-L1 Surface Expression on Leukemia Cells with the Ratio of PD-L1 mRNA Variants and with Electrophoretic Mobility. <i>Cancer Immunology Research</i> , 2016, 4, 815-819.  | 3.4 | 8         |
| 16 | Low-Dose Actinomycin D Induces Redistribution of Wild-Type and Mutated Nucleophosmin Followed by Cell Death in Leukemic Cells. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 1319-1329.  | 2.6 | 22        |
| 17 | Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2015, 10, e0127637.  | 2.5 | 26        |
| 18 | Decitabine and SAHA-Induced Apoptosis Is Accompanied by Survivin Downregulation and Potentiated by ATRA in p53-Deficient Cells. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-13.  | 4.0 | 7         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Combined Treatment with Low Concentrations of Decitabine and SAHA Causes Cell Death in Leukemic Cell Lines but Not in Normal Peripheral Blood Lymphocytes. <i>BioMed Research International</i> , 2013, 2013, 1-11.      | 1.9 | 12        |
| 20 | Generation of Reactive Oxygen Species during Apoptosis Induced by DNA-Damaging Agents and/or Histone Deacetylase Inhibitors. <i>Oxidative Medicine and Cellular Longevity</i> , 2011, 2011, 1-7.                         | 4.0 | 54        |
| 21 | Decitabine-induced apoptosis is derived by Puma and Noxa induction in chronic myeloid leukemia cell line as well as in PBL and is potentiated by SAHA. <i>Molecular and Cellular Biochemistry</i> , 2011, 350, 71-80.    | 3.1 | 19        |
| 22 | Dose-dependent effects of the caspase inhibitor Q-VD-OPh on different apoptosis-related processes. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 3334-3342.   | 2.6 | 37        |
| 23 | Suberoylanilide hydroxamic acid (SAHA) at subtoxic concentrations increases the adhesivity of human leukemic cells to fibronectin. <i>Journal of Cellular Biochemistry</i> , 2010, 109, 184-195.                         | 2.6 | 17        |
| 24 | Variations in c-Myc and p21/WAF1 expression protect normal peripheral blood lymphocytes against BimEL-mediated cell death. <i>Cell Biochemistry and Function</i> , 2009, 27, 167-175.                                    | 2.9 | 5         |
| 25 | BimEL-dependent apoptosis induced in peripheral blood lymphocytes with <i>n</i> -butyric acid is moderated by variation in expression of c-myc and p21(WAF1). <i>Cell Biochemistry and Function</i> , 2008, 26, 509-521. | 2.9 | 4         |
| 26 | Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. <i>Anti-Cancer Drugs</i> , 2007, 18, 763-772.   | 1.4 | 18        |